Veterinary Medicine Information website

FIXR Coli Ery

Not authorised
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-II, Inactivated
  • Escherichia coli, serotype O147:K88 (fimbrial adhesin F4), Inactivated
  • Escherichia coli, serotype O101:K99 (fimbrial adhesin F5), Inactivated
  • Escherichia coli, serotype K85:987P (fimbrial adhesin F6), Inactivated
  • Escherichia coli, serotype O101:K99 (fimbrial adhesin F41), Inactivated
  • Escherichia coli, serotype O149:K88 (fimbrial adhesin F4ac), Inactivated
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-64, Inactivated
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-5, Inactivated
  • Erysipelothrix rhusiopathiae, serotype 1, strain 1-203, Inactivated
Download as PDF

Product identification

Medicine name:
FIXR Coli Ery
Active substance:
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-II, Inactivated
  • Escherichia coli, serotype O147:K88 (fimbrial adhesin F4), Inactivated
  • Escherichia coli, serotype O101:K99 (fimbrial adhesin F5), Inactivated
  • Escherichia coli, serotype K85:987P (fimbrial adhesin F6), Inactivated
  • Escherichia coli, serotype O101:K99 (fimbrial adhesin F41), Inactivated
  • Escherichia coli, serotype O149:K88 (fimbrial adhesin F4ac), Inactivated
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-64, Inactivated
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-5, Inactivated
  • Erysipelothrix rhusiopathiae, serotype 1, strain 1-203, Inactivated
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-II, Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Escherichia coli, serotype O147:K88 (fimbrial adhesin F4), Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Escherichia coli, serotype O101:K99 (fimbrial adhesin F5), Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Escherichia coli, serotype K85:987P (fimbrial adhesin F6), Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Escherichia coli, serotype O101:K99 (fimbrial adhesin F41), Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Escherichia coli, serotype O149:K88 (fimbrial adhesin F4ac), Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-64, Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Erysipelothrix rhusiopathiae, serotype 2, strain 2-5, Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
  • Erysipelothrix rhusiopathiae, serotype 1, strain 1-203, Inactivated
    1.00
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AB09
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Netherlands
Package description:
  • 5 x 20 ml hydrolytic class II glass vials airtight-sealed with pierceable chlorobutyl stoppers covered with aluminium or flip-off caps in a cardboard box.
  • 1 x 50 ml hydrolytic class II glass vials airtight-sealed with pierceable chlorobutyl stoppers covered with aluminium or flip-off caps in a cardboard box.
  • 1 x 50 ml HDPE plastic vials airtight-sealed with pierceable chlorobutyl stoppers covered with aluminium or flip-off caps in a cardboard box.
  • 1 x 20 ml hydrolytic class II glass vials airtight-sealed with pierceable chlorobutyl stoppers covered with aluminium or flip-off caps in a cardboard box.
  • 1 x 100 ml hydrolytic class II glass vials airtight-sealed with pierceable chlorobutyl stoppers covered with aluminium or flip-off caps in a cardboard box.
  • 1 x 100 ml HDPE plastic vials airtight-sealed with pierceable chlorobutyl stoppers covered with aluminium or flip-off caps in a cardboard box.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Similar biological application (Article 13(4) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Kernfarm B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 125683
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0338/001

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 24/01/2022
Download